CyDex Pharmaceuticals

CyDex Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development and commercialization of drugs specifically designed to address the limitations of existing therapies. It utilizes its drug formulation technology, leveraging Captisol (a group of cyclodextrins), to develop a series of candidate products. The company's products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal treatment; and treatments for canine diseases in dogs. It has also developed Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Inhalation Solution for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. Additionally, the company licenses its technology to third parties for the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc., and changed its name in November 2007.